Stock TNGX TANGO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Market Closed - Nasdaq
Other stock markets
 01:30:00 18/06/2024 am IST 		5-day change 1st Jan Change
9.38 USD +5.04% Intraday chart for Tango Therapeutics, Inc. +31.01% -5.25%
11/06 Transcript : Tango Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
28/05 HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT
Sector Update: Health Care
MT
Tango Therapeutics Announces Discontinuation of TNG348 Program
CI
Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
British billionaire Joe Lewis fined $5 million by US judge for insider trading
RE
Multibillionaire Joe Lewis to face US sentencing for insider trading
RE
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M
MT
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says
RE
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers
CI
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q3 Revenue $10.7M
MT
Tango Therapeutics Discloses Boxer Capital Acquired 1.3 Million Shares; Tango Stock Jumps in Premarket Activity
MT
Tango Therapeutics Receives FDA Clearance to Start the TNG348 Phase 1/2 Clinical Study
CI
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for Tng348, A Novel Usp1 Inhibitor for the Treatment of Brca1/2-Mutant and Other HRD+ Cancers
CI
Tango Therapeutics Files Prospectus for Sale of 15.5 Million Shares
MT
Tango Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q2 Revenue $14.6M
MT
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients with MTAP-Deleted Solid Tumors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNGX Stock
  4. News Tango Therapeutics, Inc.
  5. Highlights